Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers
Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers has been studied in 3 papers since 2016: 3 observational studies in people; 1 in the past year. The newest paper, Oct 21, 2026: “Heterogeneous Renal Response to Therapy in Type 2 Diabetes: Albuminuria Categories”.
3 papers study it4 findingsUpdated
1 new paper in 30 daysSee all 3 papers on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers
At a glance
The findings reach people, from one lab or study. 2 independent labs in 2 countries.
“For the secondary outcome of ≥10% eGFR decline, higher adjusted odds were observed with ACEI/ARB monotherapy (OR, 1.48; 95% CI, 1.24-1.75)”
1 of its findings points the other way.
- 2 independent labs in 2 countries
- 1 finding against
- 2 of 4 findings with company ties
- Humans3
What did studies of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers find?
1Studies of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers measured one outcome, subarachnoid hemorrhage.
Subarachnoid hemorrhage
no changein humans1HR 1.04
1 study
Subarachnoid hemorrhage
no changein humans1HR 1.04
Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers were not clearly linked with subarachnoid hemorrhage in humans (known unruptured intracerebral aneurysms) (HR 1.04 (0.95-1.13)).
“Among 8034 patients with known unruptured intracerebral aneurysms, no difference in SAH with ACEI/ARBs was observed compared to alternative antihypertensive regimens”
Humansknown unruptured intracerebral aneurysmsn = 8,034
Angiotensin Inhibition Reduces the Risk of Subarachnoid Hemorrhage in Patients With Hypertension
Stroke (Hoboken, N.J.)
What is angiotensin-converting enzyme inhibitors or angiotensin receptor blockers linked with?
3Studies link angiotensin-converting enzyme inhibitors or angiotensin receptor blockers with 3 measures: urine albumin-to-creatinine ratio, ≥10% eGFR decline and subarachnoid hemorrhage.
Urine albumin-to-creatinine ratio
upin humans1
1 study
Urine albumin-to-creatinine ratio
upin humans1
Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are associated with urine albumin-to-creatinine ratio in humans (type 2 diabetes; baseline-adjusted analysis) (GMR 1.079, 95% CI 1.007–1.155).
“higher adjusted geometric mean follow-up ACR was observed with ACEI/ARB monotherapy (GMR, 1.079; 95% CI, 1.007-1.155)”
Humanstype 2 diabetes; baseline-adjusted analysismonotherapy
Heterogeneous Renal Response to Therapy in Type 2 Diabetes: Albuminuria Categories
Journal of clinical medicine
≥10% eGFR decline
upin humans1OR 1.48
1 study
≥10% eGFR decline
upin humans1OR 1.48
Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are associated with ≥10% eGFR decline in humans (type 2 diabetes; adjusted comparison with neither therapy) (OR 1.48, 95% CI 1.24–1.75).
“For the secondary outcome of ≥10% eGFR decline, higher adjusted odds were observed with ACEI/ARB monotherapy (OR, 1.48; 95% CI, 1.24-1.75)”
Humanstype 2 diabetes; adjusted comparison with neither therapymonotherapy
Heterogeneous Renal Response to Therapy in Type 2 Diabetes: Albuminuria Categories
Journal of clinical medicine
Subarachnoid hemorrhage
downin humans1HR 0.94
1 study
Subarachnoid hemorrhage
downin humans1HR 0.94
Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are linked with a lower risk of subarachnoid hemorrhage in humans (hypertension) (HR 0.94 (0.91-0.97), P<0.0001).
“Patients on ACEI/ARBs with or without other antihypertensives (n = 4.8 million, follow-up: 6.3 years) had lower rates of SAH compared with those on alternative antihypertensive regimens”
Humanshypertension
Angiotensin Inhibition Reduces the Risk of Subarachnoid Hemorrhage in Patients With Hypertension
Stroke (Hoboken, N.J.)